Novo-Nordisk A/S
N/A
USD
N/A
N/A
...
Chart
Financials
Description
NVO Company Description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
NVO Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view NVO Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
$NVO is featured in our Tom Carper strategy.
See All StrategiesAll
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of NVO by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by NVO's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of NVO in WallStreetBets Daily Discussion
NVO News
Recent insights relating to NVO
CNBC Recommendations
Recent picks made for NVO stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in NVO
Corporate Flights
Flights by private jets registered to NVO
Our Analysis